There was no apparent difference in effect on HbA1c or BMI among the different GLP1-RAs, nor was there an apparent connection between these clinical improvements and the duration of treatment
However, it remains unclear whether any observed benefits result from direct immunomodulatory effects, improvements in metabolic health, weight reduction, or other indirect mechanisms
Future research objectives must concentrate on creating prediction algorithms for appropriate receptor targeting ratios, exploring triple-agonist strategies (GLP-1/GIP/glucagon), and determining long-term safety profiles for multi-receptor therapies
Journal of Family Medicine and Primary Care, 8 (8), 25972601
The problem is, the first phase generates a burst of free radicals that can damage liver tissue if not quickly balanced by antioxidants
This isnt about willpower or restriction